The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Lian, Mingjian; Zhang, Cuixia; Zhang, Dongdong; Chen, Ping; Yang, Yuanyuan; Chen, Shi-Dong; Hong, Guolin

doi:10.1002/jcla.22875

Cited by 22 publications

(21 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lian et al reported that CA153 and CEA did not correlate with ER/PR/Her2 status. However, they stated that CEA levels exhibited statistical differences between PR-negative and PR-positive groups (2). Different from our results, Geng et al concluded that CEA levels in metastatic breast cancer were associated with breast cancer molecular subtypes (48).…”

Section: Discussioncontrasting

confidence: 99%

“…Despite the major advances in BC treatment, the prognosis remains poor. The cancer stage during diagnosis determines BC prognosis ( 2 ). The survival rate of early BC is significantly higher than that of advanced BC.…”

Section: Introductionmentioning

confidence: 99%

“…Current conventional BC diagnostic methods, including gold standard and mammography, do not identify 10-40% of early BC ( 3 , 4 ). Tumor markers are easily measured, and their clinical values in BC have been investigated ( 2 ). Established tumor markers, such as cancer antigen 153 (CA153) and carcinoembryonic antigen (CEA), are the most widely used to diagnose, monitor, and prognosticate BC ( 2 ).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

Pan

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveThis study aims to identify the potential value of flap endonuclease 1 (FEN1) as a diagnostic and prognostic marker for breast cancer (BC).MethodsELISA was used to measure serum FEN1 levels and ECLIA for CA153 and CEA levels. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value. Oncomine and UALCAN databases were used to analyze the differences in FEN1 mRNA and protein expressions. Kaplan-Meier Plotter database was then used to assess the prognostic value.ResultsBioinformatics analysis showed that the FEN1 mRNA and protein levels were significantly higher in BC tissues than in normal tissues. FEN1 was detected in culture medium of BC cell lines and serum FEN1 concentrations were significantly increased in BC patients than in cancer-free individuals. Besides, FEN1 exhibited higher diagnostic accuracy (AUC values>0.800) than CA153 and CEA for distinguishing BC patients, especially early BC, from the healthy and benign groups, or individually. Additionally, serum FEN1 levels were significantly associated with the stage (P=0.001) and lymph invasion (P=0.016), and serum FEN1 levels were increased with the development of BC. Furthermore, serum FEN1 levels were significantly decreased in post-operative patients than in pre-operative patients (P=0.016). Based on the Kaplan-Meier Plotter database, the survival analysis indicated that FEN1 overexpression was associated with poor prognoses for overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) in BC patients.ConclusionFEN1 might be a novel diagnostic and prognostic marker for BC.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

Pan

Wang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Carcinoembryonic antigen (CEA) is a glycoprotein produced by normal cells of the gastrointestinal mucosa which is involved in intercellular adhesion 9 . CEA is one of the first identified tumor markers of human breast cancer which is associated with tumor progression 10 . In veterinary medicine, dogs with mammary gland tumors held higher serum levels of CEA compared to healthy dogs 11 .…”

Section: Introductionmentioning

confidence: 99%

Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients

Fan

Ren

Liu

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The purpose of this study is to evaluate the levels and clinical diagnosis value of CA15-3, CEA, and SF in canine mammary gland tumors (CMGTs). In this study, the levels of tissues/serum CA15-3, CEA, and SF in 178 CMGT patients or healthy dogs were determined by ELISA and qRT-PCR assay. CA15-3, CEA, and SF levels of the malignant tumor group were significantly higher than that of the benign tumor group and the healthy control group. In the malignant tumor group, CA15-3 held a sensitivity of 51.8%, a specificity of 93.9%, and an accuracy of 76.8%. The sensitivity, specificity, and accuracy of CEA were 44.6%, 84.1%, and 68.1% respectively. SF held a sensitivity of 62.5%, a specificity of 85.4%, and an accuracy of 76.1%. SF showed the highest sensitivity and CA15-3 showed the highest specificity. The sensitivity, specificity, and accuracy of the combined detection of the three biomarkers in malignant tumor groups were 80.4%, 78.0%, and 80.0%, respectively, therefore combined detection increased sensitivity and accuracy but decreased specificity. In conclusion, the combined detection of serum/tissue markers CA15-3, CEA, and SF may improve the detection sensitivity of CMGTs, providing reference value for clinical application.

show abstract

“…The levels of tumor markers had a strong correlation with the advanced stages of cancer [12]. Lian et al in 2019 revealed similar findings, highlighting the role of tumor markers in breast cancer patients [13]. Based on the existing literature, serum CA15-3 can be utilized as a marker for advanced disease and even metastasis [14].…”

Section: Discussionmentioning

confidence: 98%

The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Khushk¹,

Khan

Sheraz

et al. 2021

Cureus

View full text Add to dashboard Cite

Breast cancer is a major cause of mortality among females, worldwide. The present study was intended to evaluate the significance in the management of carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) in patients with breast cancer. MethodologyA cohort study was conducted at the Jinnah Postgraduate Medical Center, Karachi, Pakistan from June 2020 to May 2021. All diagnosed cases of breast cancer who underwent surgical excision of tumor were eligible to partake. Patients who had metastatic breast cancer or had a recurrence were excluded. The patient's sociodemographic and clinical data were documented in a predefined pro forma. It included information about the age, sex, weight, as well as serum CEA and CA15-3. The CA15-3 and CEA levels for each patient were assessed by taking a 5ml blood sample and sending it to the laboratory for further workup. preoperatively on the second, seventh, and 28th postoperative days. ResultsA mean ± SD age of 52.6 ± 8.89 years was reported. Family history of breast cancer was positive in one-fourth of the patients. Nodal metastasis was negative in 114 (46.72%) patients. Three-fourth of patients had Stage II-IV with only a minority diagnosed with Stage I. The mean levels for CA15-3 in women with Stage I cancer was significantly lower on the seventh day and 28th postoperative day, compared to preoperative levels (p = 0.05). Similar associations were seen for stages II and III. Higher CEA levels were significantly associated with stage III breast cancer preoperatively (5.88 ng/ml, p = 0.05) compared to postoperative values. ConclusionThe current study revealed that preoperative values of serum CEA and CA15-3 significantly reduced postoperatively. Moreover, patients with advanced cancers had significantly higher levels of both tumor markers than those with less advanced diseases. The current study highlighted the importance of regular assessment of serum CEA and CA15-3 in breast cancer patients. Both these biomarkers are substantially elevated in breast cancer patients, preoperatively. Determining the levels of serum CEA and CA15-3 preand postoperatively may determine the prognosis and aid in forming the most optimal patient care regime with respect to the stage and subtype of cancer.

show abstract

The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

Cited by 22 publications

References 16 publications

Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients

The Role of Tumor Markers: Carcinoembryonic Antigen and Cancer Antigen 15-3 in Patients With Breast Cancer

Contact Info

Product

Resources

About